Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 11/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13023985 | 0.94 | PIM1 (0.34) | MAPTRAPGEF4PIM1MEN1KMT2A | |
| SCHEMBL13023978 | 0.93 | MAPT (0.36) | MAPTRAPGEF4PIM1TP53SMN1; SMN2 | |
| SCHEMBL13024005 | 0.93 | PIM1 (0.33) | MAPTRAPGEF4PIM1MEN1KMT2A | |
| SCHEMBL13023975 | 0.87 | RAPGEF4 (0.34) | MAPTRAPGEF4MEN1KMT2ACYP17A1 | |
| SCHEMBL13024006 | 0.86 | PIM1 (0.32) | MAPTPIM1CYP17A1 | |
| SCHEMBL13024001 | 0.86 | MAPT (0.30) | MAPT | |
| SCHEMBL13023969 | 0.85 | KMT2A (0.32) | MAPTPIM1KMT2ANPC1TP53 | |
| SCHEMBL13024003 | 0.85 | CYP17A1 (0.32) | CYP17A1NPC1RAB9A | |
| SCHEMBL13024009 | 0.85 | PIM1 (0.31) | PIM1 | |
| SCHEMBL13023991 | 0.85 | RAPGEF4 (0.32) | MAPTRAPGEF4MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286360-A1 | POLYMER COMPOUND AND POLYMER LIGHT EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286360-A1 | POLYMER COMPOUND AND POLYMER LIGHT EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286360-A1 | POLYMER COMPOUND AND POLYMER LIGHT EMITTING DEVICE USING THE SAME | IGF1R, SCO2, CRY1 | MAPT 2367/4885RAPGEF4 3709/4885PIM1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.